ArticleNAR genomics and bioinformatics2026
Predicting isocitrate dehydrogenase mutation status in acute myeloid leukemia from gene expression profiles by machine learning.
Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed machine-learning models to predict isocitrate dehydrogenase (IDH) mutation status in acute myeloid leukemia (AML) from gene expression profiles and to reconstruct missing IDH annotations across public datasets. Transcriptomic data from 19 cohorts (5844 samples) were harmonized using batch correction, and 1546 samples with known IDH status were used to train a feed-forward neural network and a logistic regression (LR) classifier within a nested cross-validation framework, followed by independent validation in the TCGA-LAML dataset. The LR model showed superior performance, achieving receiver operating characteristic area under the curve [Formula: see text] 0.994 [Formula: see text] 0.007, accuracy [Formula: see text] 0.983 [Formula: see text] 0.006, balanced accuracy [Formula: see text] 0.979 [Formula: see text] 0.005, sensitivity for the IDH-mutant (IDH-MUT) class [Formula: see text] 0.972 [Formula: see text] 0.010, and specificity [Formula: see text] 0.986 [Formula: see text] 0.008, and correctly classified all IDH-MUT cases in the independent cohort. Applying the final model to samples lacking annotations enabled reconstruction of IDH status for 4148 AML cases, expanding the number of molecularly characterized transcriptomes available for downstream analyses. Predicted groups recapitulated known IDH-associated transcriptional signatures, supporting biological validity. This work demonstrates that IDH mutation status can be accurately inferred from transcriptomic data alone and provides a scalable framework to recover missing genomic annotations, thereby enhancing the utility of public AML resources for large-scale biological and translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.